Association between per- and polyfluoroalkyl substances exposure and risk of diabetes: a systematic review and meta-analysis.
Diabetes mellitus
Meta-analysis
Per- and polyfluoroalkyl substances
Systematic review
Journal
Journal of exposure science & environmental epidemiology
ISSN: 1559-064X
Titre abrégé: J Expo Sci Environ Epidemiol
Pays: United States
ID NLM: 101262796
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
25
11
2021
accepted:
26
07
2022
revised:
26
07
2022
pubmed:
16
8
2022
medline:
21
1
2023
entrez:
15
8
2022
Statut:
ppublish
Résumé
Emerging evidence suggests that per- and polyfluoroalkyl substances (PFAS) are endocrine disruptors and may contribute to the etiology of diabetes. This study aimed to systematically review the epidemiological evidence on the associations of PFAS with mortality and morbidity of diabetes and to quantitatively evaluate the summary effect estimates of the existing literature. We searched three electronic databases for epidemiological studies concerning PFAS and diabetes published before April 1, 2022. Summary odds ratio (OR), hazard ratio (HR), or β and their 95% confidence intervals (CIs) were respectively calculated to evaluate the association between PFAS and diabetes using random-effects model by the exposure type, and dose-response meta-analyses were also performed when possible. We also assessed the risk of bias of the studies included and the confidence in the body of evidence. An initial literature search identified 1969 studies, of which 22 studies were eventually included. The meta-analyses indicated that the observed statistically significant PFAS-T2DM associations were consistent in cohort studies, while the associations were almost non-significant in case-control and cross-sectional studies. Dose-response meta-analysis showed a "parabolic-shaped" association between perfluorooctanoate acid (PFOA) exposure and T2DM risk. Available evidence was rated with "low" risk of bias, and the level of evidence for PFAS and incident T2DM was considered "moderate". Our findings suggest that PFAS exposure may increase the risk of incident T2DM, and that PFOA may exert non-monotonic dose-response effect on T2DM risk. Considering the widespread exposure, persistence, and potential for adverse health effects of PFAS, further cohort studies with improvements in expanding the sample size, adjusting the covariates, and considering different types of PFAS exposure at various doses, are needed to elucidate the putative causal associations and potential mode of action of different PFAS on diabetes. A growing body of evidence suggests that per- and polyfluoroalkyl substances (PFAS) are endocrine disruptors and may contribute to the development of diabetes. However, epidemiological evidence on the associations of PFAS and diabetes is inconsistent. We performed this comprehensive systematic review and meta-analysis to quantitatively synthesize the evidence. The findings of this study suggest that exposure to PFAS may increase diabetes risk among the general population. Reduced exposure to these "forever and everywhere chemicals" may be an important preventative approach to reducing the risk of diabetes across the population.
Sections du résumé
BACKGROUND
Emerging evidence suggests that per- and polyfluoroalkyl substances (PFAS) are endocrine disruptors and may contribute to the etiology of diabetes.
OBJECTIVES
This study aimed to systematically review the epidemiological evidence on the associations of PFAS with mortality and morbidity of diabetes and to quantitatively evaluate the summary effect estimates of the existing literature.
METHODS
We searched three electronic databases for epidemiological studies concerning PFAS and diabetes published before April 1, 2022. Summary odds ratio (OR), hazard ratio (HR), or β and their 95% confidence intervals (CIs) were respectively calculated to evaluate the association between PFAS and diabetes using random-effects model by the exposure type, and dose-response meta-analyses were also performed when possible. We also assessed the risk of bias of the studies included and the confidence in the body of evidence.
RESULTS
An initial literature search identified 1969 studies, of which 22 studies were eventually included. The meta-analyses indicated that the observed statistically significant PFAS-T2DM associations were consistent in cohort studies, while the associations were almost non-significant in case-control and cross-sectional studies. Dose-response meta-analysis showed a "parabolic-shaped" association between perfluorooctanoate acid (PFOA) exposure and T2DM risk. Available evidence was rated with "low" risk of bias, and the level of evidence for PFAS and incident T2DM was considered "moderate".
CONCLUSIONS
Our findings suggest that PFAS exposure may increase the risk of incident T2DM, and that PFOA may exert non-monotonic dose-response effect on T2DM risk. Considering the widespread exposure, persistence, and potential for adverse health effects of PFAS, further cohort studies with improvements in expanding the sample size, adjusting the covariates, and considering different types of PFAS exposure at various doses, are needed to elucidate the putative causal associations and potential mode of action of different PFAS on diabetes.
IMPACT STATEMENT
A growing body of evidence suggests that per- and polyfluoroalkyl substances (PFAS) are endocrine disruptors and may contribute to the development of diabetes. However, epidemiological evidence on the associations of PFAS and diabetes is inconsistent. We performed this comprehensive systematic review and meta-analysis to quantitatively synthesize the evidence. The findings of this study suggest that exposure to PFAS may increase diabetes risk among the general population. Reduced exposure to these "forever and everywhere chemicals" may be an important preventative approach to reducing the risk of diabetes across the population.
Identifiants
pubmed: 35970987
doi: 10.1038/s41370-022-00464-3
pii: 10.1038/s41370-022-00464-3
doi:
Substances chimiques
Endocrine Disruptors
0
Fluorocarbons
0
Caprylates
0
Alkanesulfonic Acids
0
Environmental Pollutants
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
40-55Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Tully JS, Needham LL. Serum concentrations of 11 polyfluoroalkyl compounds in the u.s. population: data from the national health and nutrition examination survey (NHANES). Environ Sci Technol. 2007;41:2237–42.
doi: 10.1021/es062686m
Sima MW, Jaffé PR. A critical review of modeling Poly- and Perfluoroalkyl Substances (PFAS) in the soil-water environment. Sci Total Environ. 2021;757:143793.
doi: 10.1016/j.scitotenv.2020.143793
Abbott BD, Wolf CJ, Schmid JE, Das KP, Zehr RD, Helfant L, et al. Perfluorooctanoic acid induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-alpha. Toxicol Sci. 2007;98:571–81.
doi: 10.1093/toxsci/kfm110
Schroeder T, Bond D, Foley J. PFAS soil and groundwater contamination via industrial airborne emission and land deposition in SW Vermont and Eastern New York State, USA. Environ Sci Process Impacts. 2021;23:291–301.
doi: 10.1039/D0EM00427H
Zeeshan M, Zhang YT, Yu S, Huang WZ, Zhou Y, Vinothkumar R, et al. Exposure to isomers of per- and polyfluoroalkyl substances increases the risk of diabetes and impairs glucose-homeostasis in Chinese adults: Isomers of C8 health project. Chemosphere. 2021;278:130486.
doi: 10.1016/j.chemosphere.2021.130486
Wang Z, DeWitt JC, Higgins CP, Cousins ITA. Never-Ending Story of Per- and Polyfluoroalkyl Substances (PFASs)? Environ Sci Technol. 2017;51:2508–18.
doi: 10.1021/acs.est.6b04806
Steenland K, Fletcher T, Savitz DA. Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ Health Perspect. 2010;118:1100–8.
doi: 10.1289/ehp.0901827
Vestergren R, Cousins IT. Tracking the pathways of human exposure to perfluorocarboxylates. Environ Sci Technol. 2009;43:5565–75.
doi: 10.1021/es900228k
Silva JAK, Martin WA, McCray JE. Air-water interfacial adsorption coefficients for PFAS when present as a multi-component mixture. J Contam Hydrol. 2021;236:103731.
doi: 10.1016/j.jconhyd.2020.103731
Chang ET, Adami HO, Boffetta P, Cole P, Starr TB, Mandel JS. A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and cancer risk in humans. Crit Rev Toxicol. 2014;44:1–81.
doi: 10.3109/10408444.2014.905767
Chang ET, Adami HO, Boffetta P, Wedner HJ, Mandel JS. A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and immunological health conditions in humans. Crit Rev Toxicol. 2016;46:279–331.
doi: 10.3109/10408444.2015.1122573
Bach C, Dauchy X, Boiteux V, Colin A, Hemard J, Sagres V, et al. The impact of two fluoropolymer manufacturing facilities on downstream contamination of a river and drinking water resources with per- and polyfluoroalkyl substances. Environ Sci Pollut Res Int. 2017;24:4916–25.
doi: 10.1007/s11356-016-8243-3
Conway BN, Badders AN, Costacou T, Arthur JM, Innes KE. Perfluoroalkyl substances and kidney function in chronic kidney disease, anemia, and diabetes. Diabetes Metab Syndr Obes. 2018;11:707–16.
doi: 10.2147/DMSO.S173809
Stratakis N, Jin DVC, Margetaki R, Valvi K, Siskos D AP, et al Prenatal Exposure to Perfluoroalkyl Substances Associated With Increased Susceptibility to Liver Injury in Children. Hepatology. 2020;72:1758–70.
doi: 10.1002/hep.31483
Kim MJ, Moon S, Oh BC, Jung D, Ji K, Choi K, et al. Association between perfluoroalkyl substances exposure and thyroid function in adults: A meta-analysis. PLoS One. 2018;13:e0197244.
doi: 10.1371/journal.pone.0197244
Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World J Diabetes. 2015;6:850–67.
doi: 10.4239/wjd.v6.i6.850
Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001;24:1936–40.
doi: 10.2337/diacare.24.11.1936
Liu H, Duan JQ, Ren XM, Li XL, Chen J, Li P, et al. [Changes of Gene Expression Profile in Cardiac Mesenchymal Cells in Patients with Type 2 Diabetes Mellitus and Screening of Their Related Environmental Chemicals]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2020;42:37–46.
Mancini FR, Rajaobelina K, Praud D, Dow C, Antignac JP, Kvaskoff M, et al. Nonlinear associations between dietary exposures to perfluorooctanoic acid (PFOA) or perfluorooctane sulfonate (PFOS) and type 2 diabetes risk in women: Findings from the E3N cohort study. Int J Hyg Environ Health. 2018;221:1054–60.
doi: 10.1016/j.ijheh.2018.07.007
Pfohl M, Marques E, Auclair A, Barlock B, Jamwal R, Goedken M, et al. An ‘Omics Approach to Unraveling the Paradoxical Effect of Diet on Perfluorooctanesulfonic Acid (PFOS) and Perfluorononanoic Acid (PFNA)-Induced Hepatic Steatosis. Toxicol Sci. 2021;180:277–94.
doi: 10.1093/toxsci/kfaa172
Wielsøe M, Long M, Ghisari M, Bonefeld-Jørgensen EC. Perfluoroalkylated substances (PFAS) affect oxidative stress biomarkers in vitro. Chemosphere. 2015;129:239–45.
doi: 10.1016/j.chemosphere.2014.10.014
Donat-Vargas C, Bergdahl IA, Tornevi A, Wennberg M, Sommar J, Kiviranta H, et al. Perfluoroalkyl substances and risk of type II diabetes: A prospective nested case-control study. Environ Int. 2019;123:390–8.
doi: 10.1016/j.envint.2018.12.026
He X, Liu Y, Xu B, Gu L, Tang W. PFOA is associated with diabetes and metabolic alteration in US men: National Health and Nutrition Examination Survey 2003–12. Sci Total Environ. 2018;625:566–74.
doi: 10.1016/j.scitotenv.2017.12.186
MacNeil J, Steenland NK, Shankar A, Ducatman A. A cross-sectional analysis of type II diabetes in a community with exposure to perfluorooctanoic acid (PFOA). Environ Res. 2009;109:997–1003.
doi: 10.1016/j.envres.2009.08.002
McGlinchey A, Sinioja T, Lamichhane S, Sen P, Bodin J, Siljander H, et al. Prenatal exposure to perfluoroalkyl substances modulates neonatal serum phospholipids, increasing risk of type 1 diabetes. Environ Int. 2020;143:105935.
doi: 10.1016/j.envint.2020.105935
Su TC, Kuo CC, Hwang JJ, Lien GW, Chen MF, Chen PC. Serum perfluorinated chemicals, glucose homeostasis and the risk of diabetes in working-aged Taiwanese adults. Environ Int. 2016;88:15–22.
doi: 10.1016/j.envint.2015.11.016
Taylor KW, Novak RF, Anderson HA, Birnbaum LS, Blystone C, Devito M, et al. Evaluation of the association between persistent organic pollutants (POPs) and diabetes in epidemiological studies: a national toxicology program workshop review. Environ Health Perspect. 2013;121:774–83.
doi: 10.1289/ehp.1205502
Qi W, Clark JM, Timme-Laragy AR, Park Y. Per- and Polyfluoroalkyl Substances and Obesity, Type 2 Diabetes and Non-alcoholic Fatty Liver Disease: A Review of Epidemiologic Findings. Toxicol Environ Chem. 2020;102:1–36.
doi: 10.1080/02772248.2020.1763997
Predieri B, Bruzzi P, Bigi E, Ciancia S, Madeo SF, Lucaccioni L, et al. Endocrine Disrupting Chemicals and Type 1 Diabetes. Int J Mol Sci. 2020;21:2937.
Howard SG. Exposure to environmental chemicals and type 1 diabetes: an update. J Epidemiol Community Health. 2019;73:483–8.
doi: 10.1136/jech-2018-210627
Bodin J, Stene LC, Nygaard UC. Can exposure to environmental chemicals increase the risk of diabetes type 1 development? Biomed Res Int. 2015;2015:208947.
doi: 10.1155/2015/208947
Lind PM, Lind L. Endocrine-disrupting chemicals and risk of diabetes: an evidence-based review. Diabetologia. 2018;61:1495–502.
doi: 10.1007/s00125-018-4621-3
Gao X, Ni W, Zhu S, Wu Y, Cui Y, Ma J, et al. Per- and polyfluoroalkyl substances exposure during pregnancy and adverse pregnancy and birth outcomes: A systematic review and meta-analysis. Environ Res. 2021;201:111632.
doi: 10.1016/j.envres.2021.111632
Wang J, Zhang J, Fan Y, Li Z, Tao C, Yan W, et al. Association between per- and polyfluoroalkyl substances and risk of gestational diabetes mellitus. Int J Hyg Environ health. 2022;240:113904.
doi: 10.1016/j.ijheh.2021.113904
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
doi: 10.1371/journal.pmed.1000097
Rooney AA, Boyles AL, Wolfe MS, Bucher JR, Thayer KA. Systematic review and evidence integration for literature-based environmental health science assessments. Environ Health Perspect. 2014;122:711–8.
doi: 10.1289/ehp.1307972
Morgan RL, Beverly B, Ghersi D, Schünemann HJ, Rooney AA, Whaley P, et al. GRADE guidelines for environmental and occupational health: A new series of articles in Environment. Int Environ Int. 2019;128:11–12.
doi: 10.1016/j.envint.2019.04.016
Cano-Sancho G, Ploteau S, Matta K, Adoamnei E, Louis GB, Mendiola J, et al. Human epidemiological evidence about the associations between exposure to organochlorine chemicals and endometriosis: Systematic review and meta-analysis. Environ Int. 2019;123:209–23.
doi: 10.1016/j.envint.2018.11.065
Lai KY, Sarkar C, Ni MY, Cheung LWT, Gallacher J, Webster C. Exposure to light at night (LAN) and risk of breast cancer: A systematic review and meta-analysis. Sci total Environ. 2021;762:143159.
doi: 10.1016/j.scitotenv.2020.143159
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
doi: 10.1186/1745-6215-8-16
Raffetti E, Donat-Vargas C, Mentasti S, Chinotti A, Donato F. Association between exposure to polychlorinated biphenyls and risk of hypertension: A systematic review and meta-analysis. Chemosphere. 2020;255:126984.
doi: 10.1016/j.chemosphere.2020.126984
Hu XF, Lowe M, Chan HM. Mercury exposure, cardiovascular disease, and mortality: A systematic review and dose-response meta-analysis. Environ Res. 2021;193:110538.
doi: 10.1016/j.envres.2020.110538
Bartell SM, Vieira VM. Critical review on PFOA, kidney cancer, and testicular cancer. J Air Waste Manag Assoc. 2021;71:663–79.
doi: 10.1080/10962247.2021.1909668
Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992;135:1301–9.
doi: 10.1093/oxfordjournals.aje.a116237
Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol. 2012;175:66–73.
doi: 10.1093/aje/kwr265
Crippa A, Discacciati A, Bottai M, Spiegelman D, Orsini N. One-stage dose-response meta-analysis for aggregated data. Stat Methods Med Res. 2019;28:1579–96.
doi: 10.1177/0962280218773122
Filippini T, Torres D, Lopes C, Carvalho C, Moreira P, Naska A, et al. Cadmium exposure and risk of breast cancer: A dose-response meta-analysis of cohort studies. Environ Int. 2020;142:105879.
doi: 10.1016/j.envint.2020.105879
Christensen KY, Raymond M, Thompson BA, Anderson HA. Perfluoroalkyl substances in older male anglers in Wisconsin. Environ Int. 2016;91:312–8.
doi: 10.1016/j.envint.2016.03.012
Park SK, Wang X, Ding N, Karvonen-Gutierrez CA, Calafat AM, Herman WH, et al. Per- and polyfluoroalkyl substances and incident diabetes in midlife women: the Study of Women’s Health Across the Nation (SWAN). Diabetologia. 2022. https://doi.org/10.1007/s00125-022-05695-5 .
doi: 10.1007/s00125-022-05695-5
Boonhat H, Lin RT. Association between leukemia incidence and mortality and residential petrochemical exposure: A systematic review and meta-analysis. Environ Int. 2020;145:106090.
doi: 10.1016/j.envint.2020.106090
Eze IC, Hemkens LG, Bucher HC, Hoffmann B, Schindler C, Künzli N, et al. Association between ambient air pollution and diabetes mellitus in Europe and North America: systematic review and meta-analysis. Environ Health Perspect. 2015;123:381–9.
doi: 10.1289/ehp.1307823
Cardenas A, Hivert MF, Gold DR, Hauser R, Kleinman KP, Lin PD, et al. Associations of Perfluoroalkyl and Polyfluoroalkyl Substances With Incident Diabetes and Microvascular Disease. Diabetes Care. 2019;42:1824–32.
doi: 10.2337/dc18-2254
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
doi: 10.1002/sim.1186
Fan SJ, Heinrich J, Bloom MS, Zhao TY, Shi TX, Feng WR, et al. Ambient air pollution and depression: A systematic review with meta-analysis up to 2019. Sci Total Environ. 2020;701:134721.
doi: 10.1016/j.scitotenv.2019.134721
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315:629–34.
doi: 10.1136/bmj.315.7109.629
Charles D, Berg V, Nøst TH, Huber S, Sandanger TM, Rylander C. Pre- and post-diagnostic blood profiles of perfluoroalkyl acids in type 2 diabetes mellitus cases and controls. Environ Int. 2020;145:106095.
doi: 10.1016/j.envint.2020.106095
Conway B, Innes KE, Long D. Perfluoroalkyl substances and beta cell deficient diabetes. J Diabetes Complications. 2016;30:993–8.
doi: 10.1016/j.jdiacomp.2016.05.001
Duan Y, Sun H, Yao Y, Li Y, Meng Y, Lu Y, et al. Serum concentrations of per-/polyfluoroalkyl substances and risk of type 2 diabetes: A case-control study. Sci Total Environ. 2021;787:147476.
doi: 10.1016/j.scitotenv.2021.147476
Han X, Meng L, Zhang G, Li Y, Shi Y, Zhang Q, et al. Exposure to novel and legacy per- and polyfluoroalkyl substances (PFASs) and associations with type 2 diabetes: A case-control study in East China. Environ Int. 2021;156:106637.
doi: 10.1016/j.envint.2021.106637
Sun Q, Zong G, Valvi D, Nielsen F, Coull B, Grandjean P. Plasma Concentrations of Perfluoroalkyl Substances and Risk of Type 2 Diabetes: A Prospective Investigation among U.S. Women. Environ Health Perspect. 2018;126:037001.
doi: 10.1289/EHP2619
Fleisch AF, Rifas-Shiman SL, Mora AM, Calafat AM, Ye X, Luttmann-Gibson H, et al. Early-Life Exposure to Perfluoroalkyl Substances and Childhood Metabolic Function. Environ Health Perspect. 2017;125:481–7.
doi: 10.1289/EHP303
Kim JH, Park HY, Jeon JD, Kho Y, Kim SK, Park MS, et al. The modifying effect of vitamin C on the association between perfluorinated compounds and insulin resistance in the Korean elderly: a double-blind, randomized, placebo-controlled crossover trial. Eur J Nutr. 2016;55:1011–20.
doi: 10.1007/s00394-015-0915-0
Karnes C, Winquist A, Steenland K. Incidence of type II diabetes in a cohort with substantial exposure to perfluorooctanoic acid. Environ Res. 2014;128:78–83.
doi: 10.1016/j.envres.2013.11.003
Steenland K, Zhao L, Winquist A, Parks C. Ulcerative colitis and perfluorooctanoic acid (PFOA) in a highly exposed population of community residents and workers in the mid-Ohio valley. Environ Health Perspect. 2013;121:900–5.
doi: 10.1289/ehp.1206449
Lind L, Zethelius B, Salihovic S, van Bavel B, Lind PM. Circulating levels of perfluoroalkyl substances and prevalent diabetes in the elderly. Diabetologia. 2014;57:473–9.
doi: 10.1007/s00125-013-3126-3
Zhang YT, Zeeshan M, Su F, Qian ZM, Dee Geiger S, Edward, et al. Associations between both legacy and alternative per- and polyfluoroalkyl substances and glucose-homeostasis: The Isomers of C8 health project in China. Environ Int. 2022;158:106913.
doi: 10.1016/j.envint.2021.106913
Cardenas A, Gold DR, Hauser R, Kleinman KP, Hivert MF, Calafat AM, et al. Plasma Concentrations of Per- and Polyfluoroalkyl Substances at Baseline and Associations with Glycemic Indicators and Diabetes Incidence among High-Risk Adults in the Diabetes Prevention Program Trial. Environ Health Perspect. 2017;125:107001.
doi: 10.1289/EHP1612
Lin CY, Chen PC, Lin YC, Lin LY. Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults. Diabetes Care. 2009;32:702–7.
doi: 10.2337/dc08-1816
Nelson JW, Hatch EE, Webster TF. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environ Health Perspect. 2010;118:197–202.
doi: 10.1289/ehp.0901165
Steenland K, Woskie S. Cohort mortality study of workers exposed to perfluorooctanoic acid. Am J Epidemiol. 2012;176:909–17.
doi: 10.1093/aje/kws171
Gilliland FD, Mandel JS. Mortality among employees of a perfluorooctanoic acid production plant. J Occup Med. 1993;35:950–4.
doi: 10.1097/00043764-199309000-00020
Leonard RC, Kreckmann KH, Sakr CJ, Symons JM. Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers. Ann Epidemiol. 2008;18:15–22.
doi: 10.1016/j.annepidem.2007.06.011
Raleigh KK, Alexander BH, Olsen GW, Ramachandran G, Morey SZ, Church TR, et al. Mortality and cancer incidence in ammonium perfluorooctanoate production workers. Occup Environ Med. 2014;71:500–6.
doi: 10.1136/oemed-2014-102109
Mastrantonio M, Bai E, Uccelli R, Cordiano V, Screpanti A, Crosignani P. Drinking water contamination from perfluoroalkyl substances (PFAS): an ecological mortality study in the Veneto Region, Italy. Eur J Public Health. 2018;28:180–5.
doi: 10.1093/eurpub/ckx066
Lundin JI, Alexander BH, Olsen GW, Church TR. Ammonium perfluorooctanoate production and occupational mortality. Epidemiology. 2009;20:921–8.
doi: 10.1097/EDE.0b013e3181b5f395
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pr. 2019;157:107843.
doi: 10.1016/j.diabres.2019.107843
Hines EP, White SS, Stanko JP, Gibbs-Flournoy EA, Lau C, Fenton SE. Phenotypic dichotomy following developmental exposure to perfluorooctanoic acid (PFOA) in female CD-1 mice: Low doses induce elevated serum leptin and insulin, and overweight in mid-life. Mol Cell Endocrinol. 2009;304:97–105.
doi: 10.1016/j.mce.2009.02.021
Lv Z, Li G, Li Y, Ying C, Chen J, Chen T, et al. Glucose and lipid homeostasis in adult rat is impaired by early-life exposure to perfluorooctane sulfonate. Environ Toxicol. 2013;28:532–42.
doi: 10.1002/tox.20747
Wan HT, Zhao YG, Leung PY, Wong CK. Perinatal exposure to perfluorooctane sulfonate affects glucose metabolism in adult offspring. PLoS One. 2014;9:e87137.
doi: 10.1371/journal.pone.0087137
Behr AC, Plinsch C, Braeuning A, Buhrke T. Activation of human nuclear receptors by perfluoroalkylated substances (PFAS). Toxicol Vitr. 2020;62:104700.
doi: 10.1016/j.tiv.2019.104700
Ishibashi H, Hirano M, Kim EY, Iwata H. In Vitro and In Silico Evaluations of Binding Affinities of Perfluoroalkyl Substances to Baikal Seal and Human Peroxisome Proliferator-Activated Receptor α. Environ Sci Technol. 2019;53:2181–8.
doi: 10.1021/acs.est.8b07273
De Silva AO, Armitage JM, Bruton TA, Dassuncao C, Heiger-Bernays W, Hu XC, et al. PFAS Exposure Pathways for Humans and Wildlife: A Synthesis of Current Knowledge and Key Gaps in Understanding. Environ Toxicol Chem. 2021;40:631–57.
doi: 10.1002/etc.4935
Pedersen KE, Letcher RJ, Sonne C, Dietz R, Styrishave B. Per- and polyfluoroalkyl substances (PFASs) - New endocrine disruptors in polar bears (Ursus maritimus)? Environ Int. 2016;96:180–9.
doi: 10.1016/j.envint.2016.07.015
Takacs ML, Abbott BD. Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol Sci. 2007;95:108–17.
doi: 10.1093/toxsci/kfl135
Botta M, Audano M, Sahebkar A, Sirtori CR, Mitro N, Ruscica M. PPAR Agonists and Metabolic Syndrome: An Established Role? Int J Mol Sci. 2018;19:1197.
Wolf CJ, Schmid JE, Lau C, Abbott BD. Activation of mouse and human peroxisome proliferator-activated receptor-alpha (PPARα) by perfluoroalkyl acids (PFAAs): further investigation of C4-C12 compounds. Reprod Toxicol. 2012;33:546–51.
doi: 10.1016/j.reprotox.2011.09.009
Gurnell M. ‘Striking the Right Balance’ in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies. PPAR Res. 2007;2007:83593.
doi: 10.1155/2007/83593
Yu XH, Zheng XL, Tang CK. Peroxisome Proliferator-Activated Receptor α in Lipid Metabolism and Atherosclerosis. Adv Clin Chem. 2015;71:171–203.
doi: 10.1016/bs.acc.2015.06.005
Park SK, Ding N, Han D. Perfluoroalkyl substances and cognitive function in older adults: Should we consider non-monotonic dose-responses and chronic kidney disease? Environ Res. 2021;192:110346.
doi: 10.1016/j.envres.2020.110346
Dhingra R, Winquist A, Darrow LA, Klein M, Steenland KA. Study of Reverse Causation: Examining the Associations of Perfluorooctanoic Acid Serum Levels with Two Outcomes. Environ Health Perspect. 2017;125:416–21.
doi: 10.1289/EHP273
Jain RB, Ducatman A. Perfluoroalkyl substances follow inverted U-shaped distributions across various stages of glomerular function: Implications for future research. Environ Res. 2019;169:476–82.
doi: 10.1016/j.envres.2018.11.033